Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 20.790
Filtrer
1.
Anim Reprod Sci ; 267: 107548, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38959672

RÉSUMÉ

We aimed to determine associations between experimentally impaired uterine clearance or treatment with ecbolic drugs on luteal development in estrous mares after insemination. In a crossover design, eight mares were treated with saline (CON), clenbuterol (CLEN), oxytocin (OXY) and carbetocin (CARB) from the day of first insemination until 2 days after ovulation. Between treatments, the mares rested for one cycle. Estrous mares were examined for the presence of free intrauterine fluid by transrectal ultrasound. Endometrial swabs for cytology and bacteriology were collected on days 1 and 14. Blood samples were collected daily before AI until day 14 after ovulation for determination of progesterone and PGF2α metabolites (PGFM). Differences between treatments were compared by a general linear model for repeated measures (SPSS 29). One mare was excluded because of a uterine infection in the control cycle. In all other mares, only minor amounts of free intrauterine fluid were present after insemination and decreased over time (P<0.05) with no treatment x time interaction. There was no effect of treatment on polymorphonucleated cells (PMN) in endometrial cytology after ovulation or PGFM secretion. Progesterone release from day 1-14 as well as pregnancy rate and conceptus size on day 14 was not influenced by treatment. In conclusion, treatment with clenbuterol does not impair uterine clearance in estrous mares resistant to endometritis. Repeated injection of the oxytocin analogue carbetocin during the early postovulatory period is not detrimental to corpus luteum function and can be recommended to enhance uterine clearance.


Sujet(s)
Ovulation , Ocytocine , Animaux , Femelle , Equus caballus , Ocytocine/pharmacologie , Ocytocine/analogues et dérivés , Ovulation/effets des médicaments et des substances chimiques , Grossesse , Corps jaune/effets des médicaments et des substances chimiques , Utérus/effets des médicaments et des substances chimiques , Études croisées , Maladies des chevaux/traitement médicamenteux , Insémination artificielle/médecine vétérinaire , Progestérone/pharmacologie , Progestérone/sang , Endomètre/effets des médicaments et des substances chimiques , Endomètre/métabolisme , Endométrite/médecine vétérinaire , Endométrite/traitement médicamenteux
2.
Gynecol Endocrinol ; 40(1): 2362244, 2024 Dec.
Article de Anglais | MEDLINE | ID: mdl-38946226

RÉSUMÉ

Ovulatory disorders are a common cause of abnormal uterine bleeding in women of reproductive age. The International Federation of Gynecology and Obstetrics currently offers a causal classification system for ovulatory disorders but does not provide clear management recommendations. There remains regional disparity in treatment practices, often influenced by institutional and insurance regulations as well as cultural and religious practices. A panel of experts evaluated current gaps in ovulatory disorder management guidelines and discussed potential strategies for addressing these unmet needs. Key gaps included a lack in consensus about the effectiveness of combined estrogen and progestogen versus progestogen alone, a paucity of evidence regarding the relative effectiveness of distinct hormonal molecules, a lack of data regarding optimal treatment duration, and limited guidance on optimal sequencing of treatment. Recommendations included development of a sequential treatment-line approach and development of a clinical guide addressing treatment scenarios common to all countries, which can then be adapted to local practices. It was also agreed that current guidelines do not address the unique clinical challenges of certain patient groups. The panel discussed how the complexity and variety of patient groups made the development of one single disease management algorithm unlikely; however, a simplified, decision-point hierarchy could potentially help direct therapeutic choices. Overall, the panel highlighted that greater advocacy for a tailored approach to the treatment of ovulatory disorders, including wider consideration of non-estrogen therapies, could help to improve care for people living with abnormal uterine bleeding due to ovarian dysfunction.


Sujet(s)
Hémorragie utérine , Humains , Femelle , Hémorragie utérine/thérapie , Hémorragie utérine/étiologie , Hémorragie utérine/diagnostic , Ovulation , Guides de bonnes pratiques cliniques comme sujet , Métrorragie/étiologie , Métrorragie/thérapie
3.
Zhongguo Zhen Jiu ; 44(7): 821-30, 2024 Jul 12.
Article de Chinois | MEDLINE | ID: mdl-38986596

RÉSUMÉ

OBJECTIVE: To observe the protective effect of acupuncture at "Zhibian" (BL 54) through "Shuidao (ST 28)" based on the PI3K/AKT/FOXO3a pathway in mice with poor ovarian response (POR), and to explore the possible mechanism of acupuncture in inhibiting ovarian granulosa cells apoptosis in POR. METHODS: A total of 45 mice with regular estrous cycles were randomly divided into a blank group, a model group and an acupuncture group, with 15 mice in each group. Mice in the model group and the acupuncture group were given triptolide suspension (50 mg•kg-1•d-1) by gavage for 2 weeks to establish POR model. After successful modeling, mice in the acupuncture group were given acupuncture at "Zhibian" (BL 54) through "Shuidao" (ST 28) for 2 weeks, once a day, 20 min each time. Ovulation induction was started the day after the intervention ended, and samples were taken from each group after ovulation induction. Vaginal smears were used to observe changes in the estrous cycle of mice. The number of oocytes retrieved, ovarian wet weight, final body weight, and ovarian index were measured. The levels of anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), estradiol (E2), and luteinizing hormone (LH) in serum were detected by ELISA. The morphology of ovarian tissue was observed by HE staining. The apoptosis of ovarian granulosa cells was detected by TUNEL staining. The mRNA expression of PI3K, AKT, and FOXO3a in ovarian tissue was detected by real-time fluorescence quantitative PCR. The protein expression of Bcl-2 associated X protein (BAX), caspase-3, phosphorylated phosphatidylinositol 3-kinase (p-PI3K), and phosphorylated protein kinase B (p-AKT) in ovarian tissue was detected by Western blot. RESULTS: Compared with the blank group, the rate of estrous cycle disorder in the model group was increased (P<0.01); compared with the model group, the rate of estrous cycle disorder in the acupuncture group was decreased (P<0.01). Compared with the blank group, the number of oocytes retrieved, ovarian wet weight, ovarian index, and final body weight in the model group were decreased (P<0.01); compared with the model group, the number of oocytes retrieved, ovarian index, and ovarian wet weight were increased (P<0.01, P<0.05), and there was no significant difference in final body weight (P>0.05) in the acupuncture group. Compared with the blank group, the serum levels of FSH and LH were increased (P<0.01), and the serum levels of AMH and E2 were decreased (P<0.01) in the model group; compared with the model group, the serum levels of FSH and LH were decreased (P<0.01, P<0.05), and the serum levels of AMH and E2 were increased (P<0.01, P<0.05) in the acupuncture group. Compared with the blank group, the number of normal developing follicles in ovarian tissue in the model group was decreased and the morphology was poor, while the number of atretic follicles increased; compared with the model group, the number, morphology, and granulosa cell structure of follicles in the acupuncture group improved to varying degrees, and the number of atretic follicles decreased. Compared with the blank group, the apoptosis rate of ovarian granulosa cells in the model group was increased (P<0.01); compared with the model group, the apoptosis rate of ovarian granulosa cells in the acupuncture group was decreased (P<0.01). Compared with the blank group, the FOXO3a mRNA expression and caspase-3 and BAX protein expression in ovarian tissue in the model group were increased (P<0.01), and the mRNA expression of PI3K and AKT and the protein expression of p-PI3K, p-AKT, and p-FOXO3a in ovarian tissue were decreased (P<0.01); compared with the model group, the mRNA expression of FOXO3a and protein expression of caspase-3 and BAX in ovarian tissue in the acupuncture group were decreased (P<0.05, P<0.01), and the mRNA expression of PI3K and AKT and the protein expression of p-PI3K, p-AKT, and p-FOXO3a in ovarian tissue were increased (P<0.01, P<0.05). CONCLUSION: Acupuncture at "Zhibian" (BL 54) through "Shuidao" (ST 28) could inhibit ovarian cell apoptosis, and improve ovarian function in POR mice, and its mechanism may be related to the regulation of key factors in the PI3K/AKT/FOXO3a pathway.


Sujet(s)
Points d'acupuncture , Thérapie par acupuncture , Protéine O3 à motif en tête de fourche , Ovaire , Protéines proto-oncogènes c-akt , Animaux , Femelle , Souris , Protéine O3 à motif en tête de fourche/métabolisme , Protéine O3 à motif en tête de fourche/génétique , Protéines proto-oncogènes c-akt/métabolisme , Protéines proto-oncogènes c-akt/génétique , Ovaire/métabolisme , Humains , Phosphatidylinositol 3-kinases/métabolisme , Phosphatidylinositol 3-kinases/génétique , Transduction du signal , Phosphatidylinositol 3-kinase/métabolisme , Phosphatidylinositol 3-kinase/génétique , Apoptose , Ovulation
4.
Sci Rep ; 14(1): 14151, 2024 06 19.
Article de Anglais | MEDLINE | ID: mdl-38898193

RÉSUMÉ

We compared the efficacy of 4 mg drospirenone (DRSP) progestin-only pills (POPs) versus combined oral contraceptive pills (COCs) containing 0.02 mg of ethinyl estradiol (EE) and 0.075 mg of gestodene (GS) in ovulation inhibition and inducing unfavorable cervical mucus changes using a delayed-starting approach. This randomized controlled trial involved 36 participants aged 18-45 years. The major outcomes included ovulation inhibition assessed using the Hoogland and Skouby score, and cervical mucus permeability, assessed using the modified World Health Organization score. The results demonstrated ovulation inhibition rates of 77.8% for the EE/GS group and 88.9% for the DRSP group. The risk ratio and absolute risk reduction were 0.50 (95% confidence interval [CI]: 0.10, 2.40) and - 0.11 (95% CI: - 0.35, 0.13), respectively, satisfying the 20% non-inferiority margin threshold. The median time to achieve unfavorable cervical mucus changes was comparable between the DRSP (3 days, interquartile range [IQR]: 6 days) and EE/GS (3.5 days, IQR: 4 days) groups. However, the DRSP group had a higher incidence of unscheduled vaginal bleeding (55.56% vs. 11.11%; p = 0.005). DRSP-only pills, initiated on days 7-9 of the menstrual cycle, were non-inferior to EE/GS pills in ovulation inhibition. However, they exhibited delayed unfavorable cervical mucus changes compared to the standard two-day backup recommendation.Clinical trial registration: Thai Clinical Trials Registry (TCTR20220819001) https://www.thaiclinicaltrials.org/show/TCTR20220819001 .


Sujet(s)
Androstènes , Contraceptifs oraux combinés , Éthinyloestradiol , Inhibition de l'ovulation , Humains , Femelle , Adulte , Éthinyloestradiol/administration et posologie , Androstènes/administration et posologie , Androstènes/effets indésirables , Jeune adulte , Adolescent , Contraceptifs oraux combinés/administration et posologie , Inhibition de l'ovulation/effets des médicaments et des substances chimiques , Méthode en simple aveugle , Adulte d'âge moyen , Norprégnènes/administration et posologie , Norprégnènes/effets indésirables , Ovulation/effets des médicaments et des substances chimiques , Glaire cervicale/effets des médicaments et des substances chimiques
5.
Nat Commun ; 15(1): 5342, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38937445

RÉSUMÉ

In vertebrates, folliculogenesis and ovulation are regulated by two distinct pituitary gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Currently, there is an intriguing consensus that a single hypothalamic neurohormone, gonadotropin-releasing hormone (GnRH), regulates the secretion of both FSH and LH, although the required timing and functions of FSH and LH are different. However, recent studies in many non-mammalian vertebrates indicated that GnRH is dispensable for FSH function. Here, by using medaka as a model teleost, we successfully identify cholecystokinin as the other gonadotropin regulator, FSH-releasing hormone (FSH-RH). Our histological and in vitro analyses demonstrate that hypothalamic cholecystokinin-expressing neurons directly affect FSH cells through the cholecystokinin receptor, Cck2rb, thereby increasing the expression and release of FSH. Remarkably, the knockout of this pathway minimizes FSH expression and results in a failure of folliculogenesis. Here, we propose the existence of the "dual GnRH model" in vertebrates that utilize both FSH-RH and LH-RH.


Sujet(s)
Hormone folliculostimulante , Hormone de libération des gonadotrophines , Hypothalamus , Oryzias , Animaux , Hormone de libération des gonadotrophines/métabolisme , Hormone de libération des gonadotrophines/génétique , Hormone folliculostimulante/métabolisme , Hormone folliculostimulante/génétique , Femelle , Oryzias/métabolisme , Oryzias/génétique , Hypothalamus/métabolisme , Neurones/métabolisme , Hormone lutéinisante/métabolisme , Follicule ovarique/métabolisme , Ovulation/génétique
6.
Trials ; 25(1): 364, 2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38845035

RÉSUMÉ

BACKGROUND: Women with polycystic ovary syndrome (PCOS) are usually selected to undergo an ovulation induction regimen or a programmed regimen for endometrial preparation in the frozen-thawed embryo transfer (FET) during their IVF/ICSI treatment. The programmed regimen permits flexible scheduling of embryo transfer but requires long-term usage of exogenous estrogen and higher dosages of luteal support while the letrozole ovulation regimen needs lower dosages of luteal support only. Recently, multiple studies have shown that the letrozole ovulation regimen can improve pregnancy outcomes of FET in women with PCOS compared with the programmed regimen. However, most of these studies are retrospective, and prospective studies are urgently needed the evidence from the perspective study is insufficient. METHODS/DESIGN: We are undertaking a multicentre, randomized, controlled clinical trial of an endometrial preparation regimen for FET in women with PCOS. The eligible women are randomly assigned to either the letrozole ovulation regimen or the programmed regimen for endometrial preparation. The primary outcome is the clinical pregnancy rate. DISCUSSION: The results of this study will provide evidence for whether the letrozole ovulation regimen for endometrial preparation could improve pregnancy outcomes in PCOS women undergoing FET. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200062244. Registered on 31 July 2022.


Sujet(s)
Transfert d'embryon , Létrozole , Études multicentriques comme sujet , Induction d'ovulation , Syndrome des ovaires polykystiques , Taux de grossesse , Essais contrôlés randomisés comme sujet , Humains , Syndrome des ovaires polykystiques/traitement médicamenteux , Femelle , Létrozole/administration et posologie , Grossesse , Transfert d'embryon/méthodes , Induction d'ovulation/méthodes , Cryoconservation , Résultat thérapeutique , Fécondostimulants féminins/administration et posologie , Fécondostimulants féminins/usage thérapeutique , Fécondostimulants féminins/effets indésirables , Ovulation/effets des médicaments et des substances chimiques , Chine , Adulte , Infertilité féminine/thérapie
7.
Endocrinology ; 165(7)2024 May 27.
Article de Anglais | MEDLINE | ID: mdl-38889246

RÉSUMÉ

Follicular androgens are important for successful ovulation and fertilization. The classical nuclear androgen receptor (AR) is a transcription factor expressed in the cells of the ovarian follicle. Androgen actions can also occur via membrane androgen receptor SLC39A9. Studies in fish ovary demonstrated that androgens bind to SLC39A9 and increase intracellular zinc to regulate ovarian cell function. To determine if SLC39A9 is expressed and functional in the key cell types of the mammalian ovulatory follicle, adult female cynomolgus macaques underwent ovarian stimulation. Ovaries or ovarian follicular aspirates were harvested at 0, 12, 24, and 36 hours after human chorionic gonadotropin (hCG). SLC39A9 and AR mRNA and protein were present in granulosa, theca, and vascular endothelial cells across the entire 40-hour ovulatory window. Testosterone, bovine serum albumin-conjugated testosterone (BSA-T), and androstenedione stimulated zinc influx in granulosa, theca, and vascular endothelial cells. The SLC39A9-selective agonist (-)-epicatechin also stimulated zinc influx in vascular endothelial cells. Taken together, these data support the conclusion that SLC39A9 activation via androgen induces zinc influx in key ovarian cells. Testosterone, BSA-T, and androstenedione each increased proliferation in vascular endothelial cells, indicating the potential involvement of SLC39A9 in ovulatory angiogenesis. Vascular endothelial cell migration also increased after treatment with testosterone, but not after treatment with BSA-T or androstenedione, suggesting that androgens stimulate vascular endothelial cell migration through nuclear AR but not SLC39A9. The presence of SLC39A9 receptors and SLC39A9 activation by follicular androstenedione concentrations suggests that androgen activation of ovarian SLC39A9 may regulate ovulatory changes in the mammalian follicle.


Sujet(s)
Macaca fascicularis , Follicule ovarique , Ovulation , Récepteurs aux androgènes , Animaux , Femelle , Récepteurs aux androgènes/métabolisme , Récepteurs aux androgènes/génétique , Follicule ovarique/métabolisme , Follicule ovarique/effets des médicaments et des substances chimiques , Zinc/métabolisme , Testostérone/métabolisme , Cellules endothéliales/métabolisme , Transporteurs de cations/métabolisme , Transporteurs de cations/génétique , Membrane cellulaire/métabolisme , Cellules thécales/métabolisme , Cellules de la granulosa/métabolisme , Cellules de la granulosa/effets des médicaments et des substances chimiques , Gonadotrophine chorionique/pharmacologie
8.
Front Endocrinol (Lausanne) ; 15: 1401975, 2024.
Article de Anglais | MEDLINE | ID: mdl-38846489

RÉSUMÉ

Background: Vitamin D binding protein (DBP) might increase substantially after ovarian stimulation and hence could be associated with IVF/ICSI outcomes because it determines the fraction of free bioavailable 25(OH) vitamin D. In this study, we aim to determine whether DBP is associated with E2 level after ovarian stimulation and IVF/ICSI outcomes. Design: Post-hoc analysis of a prospective observational cohort. Setting: Single-center study. Participants: 2569 women receiving embryo transfer. Intervention: None. Main outcome measures: The main outcomes were oocyte and embryo quality as well as pregnancy outcomes. Results: DBP concentration correlates with E2 on hCG day (=day of inducing ovulation with hCG; correlation coefficient r = 0.118, P<0.001) and E2 x-fold change to baseline level (r = 0.108, P<0.001). DBP is also positively correlated with total 25(OH)D (r = 0.689, R2 = 0.475, P<0.001) and inversely with free 25(OH)D (r=-0.424, R2=0.179, P<0.001), meaning that E2-stimulated DBP synthesis results in a decrease of free 25(OH)D during ovarian stimulation. However, such alteration does not affect IVF/ICSI outcomes when considering confounding factors, such as the number and quality of oocytes nor embryo quality as well as pregnancy outcomes. Conclusion: DBP concentration correlates with the degree of E2 increase after ovarian stimulation. DBP is also positively correlated with total 25(OH)D and inversely with free 25(OH)D, suggesting that the proportion of free 25(OH)D decreases during ovarian stimulation caused by E2-stimulated DBP synthesis. However, such alteration does not affect clinical IVF/ICSI outcomes.


Sujet(s)
Gonadotrophine chorionique , Fécondation in vitro , Induction d'ovulation , Ovulation , Issue de la grossesse , Protéine de liaison à la vitamine D , Humains , Femelle , Grossesse , Protéine de liaison à la vitamine D/sang , Adulte , Induction d'ovulation/méthodes , Gonadotrophine chorionique/administration et posologie , Ovulation/effets des médicaments et des substances chimiques , Études prospectives , Fécondation in vitro/méthodes , Oestrogènes/administration et posologie , Transfert d'embryon , Taux de grossesse , Injections intracytoplasmiques de spermatozoïdes
9.
Int J Mol Sci ; 25(12)2024 Jun 13.
Article de Anglais | MEDLINE | ID: mdl-38928237

RÉSUMÉ

The physiology of reproduction has been of interest to researchers for centuries. The purpose of this work is to review the development of our knowledge on the neuroendocrine background of the regulation of ovulation. We first describe the development of the pituitary gland, the structure of the median eminence (ME), the connection between the hypothalamus and the pituitary gland, the ovarian and pituitary hormones involved in ovulation, and the pituitary cell composition. We recall the pioneer physiological and morphological investigations that drove development forward. The description of the supraoptic-paraventricular magnocellular and tuberoinfundibular parvocellular systems and recognizing the role of the hypophysiotropic area were major milestones in understanding the anatomical and physiological basis of reproduction. The discovery of releasing and inhibiting hormones, the significance of pulse and surge generators, the pulsatile secretion of the gonadotropin-releasing hormone (GnRH), and the subsequent pulsatility of luteinizing (LH) and follicle-stimulating hormones (FSH) in the human reproductive physiology were truly transformative. The roles of three critical neuropeptides, kisspeptin (KP), neurokinin B (NKB), and dynorphin (Dy), were also identified. This review also touches on the endocrine background of human infertility and assisted fertilization.


Sujet(s)
Système neuroendocrinien , Ovulation , Humains , Ovulation/physiologie , Femelle , Système neuroendocrinien/physiologie , Système neuroendocrinien/métabolisme , Animaux , Hypophyse/métabolisme , Kisspeptines/métabolisme , Neurokinine B/métabolisme , Hormone lutéinisante/métabolisme , Hormone de libération des gonadotrophines/métabolisme , Dynorphines/métabolisme , Hypothalamus/métabolisme , Hypothalamus/physiologie
10.
Article de Allemand | MEDLINE | ID: mdl-38701799

RÉSUMÉ

OBJECT AND AIM: This study presents the individual course of estradiol-17ß and progesterone concentrations in blood during the reproductive cycle in mares in order to point out physiological differences between individual animals and to aid in the interpretation of hormone values. MATERIAL AND METHODS: Concentrations of estradiol-17ß and progesterone were determined in seven mares over the course of their cycle. One mare was excluded from the study due to a physiologically deviating cycle. In addition, the mares' ovaries were examined via ultrasound on a daily basis in order to match the hormone values to morphological changes of the ovaries. RESULTS: In some cases, the mares showed considerable individual differences in their hormone concentrations, which also differed from the published comparative values in the literature. For example, two mares showed progesterone levels above basal levels at the time of ovulation. The postovulatory progesterone concentrations of the mares are characterized by marked fluctuations, which makes it difficult to provide reference values in the different sections of the corpus luteum phase. The length of the plateau phases averaged 12.3±1.5 days. The mare with double ovulation showed the highest progesterone concentrations. CONCLUSION: The measurement of plasma progesterone levels in mares should be interpreted only in the context of other test results. The very wide variation in estradiol-17ß concentrations makes it questionable whether the determination of this hormone value is of diagnostic value. CLINICAL RELEVANCE: When interpreting steroid hormone values in the ingravid cycle of a mare, the individual concentration courses must be taken into consideration, as they may deviate significantly from the published reference values.


Sujet(s)
Oestradiol , Progestérone , Animaux , Equus caballus/sang , Equus caballus/physiologie , Femelle , Progestérone/sang , Oestradiol/sang , Cycle oestral/physiologie , Cycle oestral/sang , Ovaire/physiologie , Ovaire/imagerie diagnostique , Ovaire/anatomie et histologie , Ovulation/physiologie , Ovulation/sang
11.
Cells ; 13(9)2024 Apr 28.
Article de Anglais | MEDLINE | ID: mdl-38727294

RÉSUMÉ

Information on long-term effects of postovulatory oocyte aging (POA) on offspring is limited. Whether POA affects offspring by causing oxidative stress (OS) and mitochondrial damage is unknown. Here, in vivo-aged (IVA) mouse oocytes were collected 9 h after ovulation, while in vitro-aged (ITA) oocytes were obtained by culturing freshly ovulated oocytes for 9 h in media with low, moderate, or high antioxidant potential. Oocytes were fertilized in vitro and blastocysts transferred to produce F1 offspring. F1 mice were mated with naturally bred mice to generate F2 offspring. Both IVA and the ITA groups in low antioxidant medium showed significantly increased anxiety-like behavior and impaired spatial and fear learning/memory and hippocampal expression of anxiolytic and learning/memory-beneficial genes in both male and female F1 offspring. Furthermore, the aging in both groups increased OS and impaired mitochondrial function in oocytes, blastocysts, and hippocampus of F1 offspring; however, it did not affect the behavior of F2 offspring. It is concluded that POA caused OS and damaged mitochondria in aged oocytes, leading to defects in anxiety-like behavior and learning/memory of F1 offspring. Thus, POA is a crucial factor that causes psychological problems in offspring, and antioxidant measures may be taken to ameliorate the detrimental effects of POA on offspring.


Sujet(s)
Comportement animal , Mitochondries , Ovocytes , Stress oxydatif , Animaux , Ovocytes/métabolisme , Mitochondries/métabolisme , Femelle , Souris , Mâle , Ovulation , Anxiété/métabolisme , Anxiété/anatomopathologie , Antioxydants/métabolisme , Hippocampe/métabolisme , Hippocampe/anatomopathologie , Blastocyste/métabolisme , Vieillissement de la cellule , Mémoire
12.
Genes (Basel) ; 15(5)2024 05 12.
Article de Anglais | MEDLINE | ID: mdl-38790245

RÉSUMÉ

Insulin receptor signaling promotes cell differentiation, proliferation, and growth which are essential for oocyte maturation, embryo implantation, endometrial decidualization, and placentation. The dysregulation of insulin signaling in women with metabolic syndromes including diabetes exhibits poor pregnancy outcomes that are poorly understood. We utilized the Cre/LoxP system to target the tissue-specific conditional ablation of insulin receptor (Insr) and insulin-like growth factor-1 receptor (Igf1r) using an anti-Mullerian hormone receptor 2 (Amhr2) Cre-driver which is active in ovarian granulosa and uterine stromal cells. Our long-term goal is to examine insulin-dependent molecular mechanisms that underlie diabetic pregnancy complications, and our conditional knockout models allow for such investigation without confounding effects of ligand identity, source and cross-reactivity, or global metabolic status within dams. Puberty occurred with normal timing in all conditional knockout models. Estrous cycles progressed normally in Insrd/d females but were briefly stalled in diestrus in Igf1rd/d and double receptor (DKO) mice. The expression of vital ovulatory genes (Lhcgr, Pgr, Ptgs2) was not significantly different in 12 h post-hCG superovulated ovaries in knockout mice. Antral follicles exhibited an elevated apoptosis of granulosa cells in Igf1rd/d and DKO mice. However, the distribution of ovarian follicle subtypes and subsequent ovulations was normal in all insulin receptor mutants compared to littermate controls. While ovulation was normal, all knockout lines were subfertile suggesting that the loss of insulin receptor signaling in the uterine stroma elicits implantation and decidualization defects responsible for subfertility in Amhr2-Cre-derived insulin receptor mutants.


Sujet(s)
Ovaire , Récepteur IGF de type 1 , Récepteur à l'insuline , Animaux , Femelle , Souris , Grossesse , Cellules de la granulosa/métabolisme , Cellules de la granulosa/anatomopathologie , Infertilité féminine/génétique , Infertilité féminine/métabolisme , Infertilité féminine/anatomopathologie , Souris knockout , Ovaire/métabolisme , Ovaire/anatomopathologie , Ovulation/génétique , Récepteur IGF de type 1/génétique , Récepteur IGF de type 1/métabolisme , Récepteur à l'insuline/génétique , Récepteur à l'insuline/métabolisme , Transduction du signal/génétique
13.
Zhongguo Zhong Yao Za Zhi ; 49(8): 2016-2022, 2024 Apr.
Article de Chinois | MEDLINE | ID: mdl-38812218

RÉSUMÉ

This paper aims to study the therapeutic effect and safety of Bushen Culuan Formula in the treatment of patients with infertility caused by hyperprolactinemia. Sixty patients with infertility caused by hyperprolactinemia of kidney deficiency and blood stasis were divided into the treatment group(Bushen Culuan Formula + Bromocriptine Mesylate Tablets placebo) and the control group(Bromocriptine Mesylate Tablets + Bushen Culuan Formula placebo), and ovulation rate, pregnancy rate, serum sex hormones, basal body temperature(BBT), and traditional Chinese medicine(TCM) symptom scores were observed. The results showed the clinical effective rate was 90.00% in the treatment group and 80.00% in the control group. The treatment group was able to significantly reduce the PRL level and increase the pregnancy rate, and it was superior to the control group in increasing the BBT biphasic ratio, improving the TCM symptom scores, and enhancing the ovulation rate. The results show that Bushen Culuan Formula is safe and reliable in treating ovulatory disorder infertility caused by hyperprolactinemia, with remarkable effects.


Sujet(s)
Médicaments issus de plantes chinoises , Hyperprolactinémie , Infertilité féminine , Ovulation , Hyperprolactinémie/traitement médicamenteux , Hyperprolactinémie/complications , Humains , Femelle , Médicaments issus de plantes chinoises/administration et posologie , Médicaments issus de plantes chinoises/usage thérapeutique , Adulte , Ovulation/effets des médicaments et des substances chimiques , Infertilité féminine/traitement médicamenteux , Infertilité féminine/étiologie , Grossesse , Jeune adulte
14.
Zhongguo Zhong Yao Za Zhi ; 49(8): 1996-2005, 2024 Apr.
Article de Chinois | MEDLINE | ID: mdl-38812216

RÉSUMÉ

Transcriptomics was used to investigate the mechanism of action of Bushen Culuan Formula in the treatment of infertility caused by hyperprolactinemia(HPRL), and animal experiments were carried out to verify the results. After establishing an animal model of HPRL-induced infertility, the mice were divided into normal group, model group, Bushen Culuan Formula groups with high-, medium-, and low-doses, and bromocriptine group, and they were observed in terms of the estrous cycle, gonadal index, serum sex hormones, morphology of ovary and mammary gland, follicle count, and fertility. The results showed that the Bushen Culuan Formula could effectively restore the estrous cycle, down-regulate the levels of prolactin(PRL), follicle-stimulating hormone(FSH), and luteinizing hormone(LH), up-regulate the level of estradiol(E_2), increase the number of primordial follicles and sinus follicles, and improve the ovulation rate and fertility of mice. Through RNA sequencing combined with biosignature analysis, Bushen Culuan Formula may regulate the metabolism of lipids, antioxidant enzymes, and other substances in the cells of the ovary and pituitary gland through the signaling pathways of cAMP-PKA, Kiss-1/GPR54, and Hippo and exert therapeutic effects. The results of animal experiments showed that Bushen Culuan Formula could up-regulate serum dopamine(DA) level and pituitary DRD2 expression, down-regulate hypothalamus and ovary cAMP levels, as well as protein expressions of the pituitary gland and ovary PKA, CREB, and p-CREB, and treat HPRL-induced infertility by regulating the cAMP-PKA signaling pathway.


Sujet(s)
Médicaments issus de plantes chinoises , Hormones sexuelles stéroïdiennes , Hyperprolactinémie , Ovulation , Animaux , Femelle , Souris , Médicaments issus de plantes chinoises/administration et posologie , Médicaments issus de plantes chinoises/pharmacologie , Hyperprolactinémie/traitement médicamenteux , Ovulation/effets des médicaments et des substances chimiques , Humains , Hormone folliculostimulante/sang , Hormone lutéinisante/sang , Ovaire/effets des médicaments et des substances chimiques , Ovaire/métabolisme , Cycle oestral/effets des médicaments et des substances chimiques , Récepteur D2 de la dopamine/métabolisme , Récepteur D2 de la dopamine/génétique
15.
Front Neural Circuits ; 18: 1409349, 2024.
Article de Anglais | MEDLINE | ID: mdl-38752168

RÉSUMÉ

Sexual behavior is crucial for reproduction in many animals. In many vertebrates, females exhibit sexual behavior only during a brief period surrounding ovulation. Over the decades, studies have identified the roles of ovarian sex hormones, which peak in levels around the time of ovulation, and the critical brain regions involved in the regulation of female sexual behavior. Modern technical innovations have enabled a deeper understanding of the neural circuit mechanisms controlling this behavior. In this review, I summarize our current knowledge and discuss the neural circuit mechanisms by which female sexual behavior occurs in association with the ovulatory phase of their cycle.


Sujet(s)
Comportement sexuel chez les animaux , Animaux , Femelle , Comportement sexuel chez les animaux/physiologie , Humains , Encéphale/physiologie , Hormones sexuelles stéroïdiennes/physiologie , Hormones sexuelles stéroïdiennes/métabolisme , Ovulation/physiologie , Voies nerveuses/physiologie
16.
Lancet ; 403(10443): 2489-2503, 2024 Jun 08.
Article de Anglais | MEDLINE | ID: mdl-38782004

RÉSUMÉ

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Obesity exacerbates the reproductive complications of PCOS; however, the management of obesity in women with PCOS remains a large unmet clinical need. Observational studies have indicated that bariatric surgery could improve the rates of ovulatory cycles and prospects of fertility; however, the efficacy of surgery on ovulation rates has not yet been compared with behavioural modifications and medical therapy in a randomised trial. The aim of this study was to compare the safety and efficacy of bariatric surgery versus medical care on ovulation rates in women with PCOS, obesity, and oligomenorrhoea or amenorrhoea. METHODS: In this multicentre, open-label, randomised controlled trial, 80 women older than 18 years, with a diagnosis of PCOS based on the 2018 international evidence-based guidelines for assessing and managing PCOS, and a BMI of 35 kg/m2 or higher, were recruited from two specialist obesity management centres and via social media. Participants were randomly assigned at a 1:1 ratio to either vertical sleeve gastrectomy or behavioural interventions and medical therapy using a computer-generated random sequence (PLAN procedure in SAS) by an independent researcher not involved with any other aspect of the clinical trial. The median age of the entire cohort was 31 years and 79% of participants were White. The primary outcome was the number of biochemically confirmed ovulatory events over 52 weeks, and was assessed using weekly serum progesterone measurements. The primary endpoint included the intention-to-treat population and safety analyses were per-protocol population. This study is registered with the ISRCTN registry (ISRCTN16668711). FINDINGS: Participants were recruited from Feb 20, 2020 to Feb 1, 2021. 40 participants were assigned to each group and there were seven dropouts in the medical group and ten dropouts in the surgical group. The median number of ovulations was 6 (IQR 3·5-10·0) in the surgical group and 2 (0·0-4·0) in the medical group. Women in the surgical group had 2.5 times more spontaneous ovulations compared with the medical group (incidence rate ratio 2·5 [95% CI 1·5-4·2], p<0·0007). There were more complications in the surgical group than the medical group, although without long-term sequelae. There were 24 (66·7%) adverse events in the surgical group and 12 (30·0%) in the medical group. There were no treatment-related deaths. INTERPRETATION: Bariatric surgery was more effective than medical care for the induction of spontaneous ovulation in women with PCOS, obesity, and oligomenorrhoea or amenorrhoea. Bariatric surgery could, therefore, enhance the prospects of spontaneous fertility in this group of women. FUNDING: The Jon Moulton Charity Trust.


Sujet(s)
Chirurgie bariatrique , Obésité , Ovulation , Syndrome des ovaires polykystiques , Humains , Syndrome des ovaires polykystiques/complications , Syndrome des ovaires polykystiques/chirurgie , Femelle , Adulte , Chirurgie bariatrique/effets indésirables , Chirurgie bariatrique/méthodes , Obésité/complications , Obésité/chirurgie , Oligoménorrhée , Résultat thérapeutique , Aménorrhée/étiologie , Jeune adulte , Gastrectomie/méthodes , Gastrectomie/effets indésirables , Infertilité féminine/étiologie
17.
Cell Cycle ; 23(6): 703-712, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38819114

RÉSUMÉ

Surfeit locus protein 4 is a cargo receptor mediating cargo transport from the endoplasmic reticulum lumen to the Golgi apparatus. Loss of Surf4 gene led to embryonic lethality in mice. However, the role of Surf4 during oocyte development remains unknown. In this study, we generated the mouse model with oocyte-specific knockout of Surf4 gene. We found that adult mice with deletion of Surf4 showed normal folliculogenesis, ovulation and fertility. However, loss of Surf4 slightly impaired oocyte quality, thus led to partial oocyte meiotic arrest and reduced ratio of blastocyst formation. Consistent with this, the distribution of endoplasmic reticulum was disturbed in Surf4-deficient oocytes in mice. These results demonstrated that although Surf4 is dispensable for female mouse fertility, Surf4 modulates endoplasmic reticulum arrangement and participates in regulation of developmental competence of oocytes.


Sujet(s)
Réticulum endoplasmique , Méiose , Protéines membranaires , Souris knockout , Ovocytes , Animaux , Ovocytes/métabolisme , Ovocytes/cytologie , Femelle , Réticulum endoplasmique/métabolisme , Méiose/génétique , Souris , Protéines membranaires/métabolisme , Protéines membranaires/génétique , Fécondité/génétique , Ovulation/génétique , Souris de lignée C57BL , Blastocyste/métabolisme , Blastocyste/cytologie
18.
Domest Anim Endocrinol ; 88: 106852, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38701638

RÉSUMÉ

Mares resume ovarian activity rapidly after foaling. Besides follicle-stimulating hormone (FSH) and luteinizing hormone (LH), the pituitary synthesizes prolactin and growth hormone which stimulate insulin-like growth factor (IGF) synthesis in the liver. We tested the hypothesis that follicular growth is initiated already antepartum, mares with early and delayed ovulation differ in IGF-1 release and that there is an additional IGF-1 synthesis in the placenta. Plasma concentrations of LH, FSH, IGF-1, IGF-2, activin and prolactin. IGF-1, IGF-2, prolactin and their receptors in placental tissues were analyzed at the mRNA and protein level. Follicular growth was determined from 15 days before to 15 days after foaling in 14 pregnancies. Mares ovulating within 15 days postpartum formed group OV (n=5) and mares not ovulating within 15 days group NOV (n=9). Before foaling, follicles with a diameter >1 cm were present in all mares and their number increased over time (p<0.05). Follicle growth after foaling was more pronounced in OV mares (day p<0.001, group p<0.05, day x group p<0.05) in parallel to an increase in LH concentration (p<0.001, day x group p<0.001) while FSH increased (p<0.001) similarly in both groups. Plasma concentrations of IGF-1 and prolactin peaked one day after foaling (p<0.001). The IGF-1 mRNA abundance was higher in the allantochorion but lower in the amnion of OV versus NOV mares (group p=0.01, localization x group p<0.01). The IGF-1 receptor mRNA was most abundant in the allantochorion (p<0.001) and IGF-1 protein was expressed in placental tissue without differences between groups. In conclusion, follicular growth in mares is initiated before foaling and placental IGF-1 may enhance resumption of ovulatory cycles.


Sujet(s)
Facteur de croissance IGF-I , Ovaire , Période du postpartum , Prolactine , Animaux , Equus caballus/physiologie , Femelle , Période du postpartum/physiologie , Prolactine/sang , Prolactine/métabolisme , Grossesse , Facteur de croissance IGF-I/métabolisme , Facteur de croissance IGF-I/génétique , Ovaire/physiologie , Ovaire/métabolisme , ARN messager/métabolisme , ARN messager/génétique , Placenta/métabolisme , Hormone lutéinisante/sang , Hormone lutéinisante/métabolisme , Follicule ovarique/physiologie , Follicule ovarique/métabolisme , Hormone folliculostimulante/sang , Hormone folliculostimulante/métabolisme , Ovulation/physiologie , Facteur de croissance IGF-II/génétique , Facteur de croissance IGF-II/métabolisme , Activines/métabolisme , Récepteur prolactine/génétique , Récepteur prolactine/métabolisme
19.
Domest Anim Endocrinol ; 88: 106854, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38733943

RÉSUMÉ

This study evaluated the efficiency of prostaglandin F2α (PGF) to hasten ovulation in weaned sows. In experiment I, weaned sows detected in estrus (0 h) received: no hormone (Control; n = 56); 0.5 mg PGF IM at 0 h and 2 h (PGF0; n = 56); or 0.5 mg PGF IM at 24 h and 26 h (PGF24; n = 55). In experiment II, weaned sows that did not express estrus signs until 72 h after weaning (0 h) were assigned to: no hormone (Control; n = 45); 10 µg buserelin acetate IM at 0 h (Buserelin; n = 43); 0.5 mg PGF IM at 34 h and 36 h (PGF; n = 44); or 10 µg buserelin acetate IM at 0 h plus 0.5 mg PGF IM at 34 h and 36 h (Buserelin + PGF; n = 45). In experiment I, no effect of PGF on the interval treatment onset to ovulation was observed (P > 0.05), and no treatment effect was observed on the relative or cumulative proportion of females that ovulated post-treatment onset (P > 0.05). In experiment II, treatment onset to ovulation interval was shorter for Buserelin group than for PGF group (P < 0.05), and a higher cumulative percentage of Buserelin treated sows ovulated up to 48 h compared to PGF and Control groups (P < 0.01), with no differences from Buserelin + PGF. Treatments did not affect total number of piglets born in both experiments (P > 0.05). In conclusion, PGF did not hasten ovulation timing or affect litter size in weaned sows.


Sujet(s)
Buséréline , Dinoprost , Ovulation , Animaux , Femelle , Dinoprost/pharmacologie , Dinoprost/administration et posologie , Suidae/physiologie , Ovulation/effets des médicaments et des substances chimiques , Ovulation/physiologie , Buséréline/pharmacologie , Buséréline/administration et posologie , Sevrage , Induction d'ovulation/médecine vétérinaire , Induction d'ovulation/méthodes
20.
Reprod Biol Endocrinol ; 22(1): 52, 2024 May 06.
Article de Anglais | MEDLINE | ID: mdl-38711160

RÉSUMÉ

BACKGROUND: Elevated FSH often occurs in women of advanced maternal age (AMA, age ≥ 35) and in infertility patients undergoing controlled ovarian stimulation (COS). There is controversy on whether high endogenous FSH contributes to infertility and whether high exogenous FSH adversely impacts patient pregnancy rates. METHODS: The senescence-accelerated mouse-prone-8 (SAMP8) model of female reproductive aging was employed to assess the separate impacts of age and high FSH activity on the percentages (%) of viable and mature ovulated oocytes recovered after gonadotropin treatment. Young and midlife mice were treated with the FSH analog equine chorionic gonadotropin (eCG) to model both endogenous FSH elevation and exogenous FSH elevation. Previously we showed the activin inhibitor ActRIIB:Fc increases oocyte quality by preventing chromosome and spindle misalignments. Therefore, ActRIIB:Fc treatment was performed in an effort to increase % oocyte viability and % oocyte maturation. RESULTS: The high FSH activity of eCG is ootoxic to ovulatory oocytes, with greater decreases in % viable oocytes in midlife than young mice. High FSH activity of eCG potently inhibits oocyte maturation, decreasing the % of mature oocytes to similar degrees in young and midlife mice. ActRIIB:Fc treatment does not prevent eCG ootoxicity, but it restores most oocyte maturation impeded by eCG. CONCLUSIONS: FSH ootoxicity to ovulatory oocytes and FSH maturation inhibition pose a paradox given the well-known pro-growth and pro-maturation activities of FSH in the earlier stages of oocyte growth. We propose the FOOT Hypothesis ("FSH OoToxicity Hypothesis), that FSH ootoxicity to ovulatory oocytes comprises a new driver of infertility and low pregnancy success rates in DOR women attempting spontaneous pregnancy and in COS/IUI patients, especially AMA women. We speculate that endogenous FSH elevation also contributes to reduced fecundity in these DOR and COS/IUI patients. Restoration of oocyte maturation by ActRIB:Fc suggests that activin suppresses oocyte maturation in vivo. This contrasts with prior studies showing activin A promotes oocyte maturation in vitro. Improved oocyte maturation with agents that decrease endogenous activin activity with high specificity may have therapeutic benefit for COS/IVF patients, COS/IUI patients, and DOR patients attempting spontaneous pregnancies.


Sujet(s)
Récepteur activine, type 2 , Ovocytes , Animaux , Femelle , Ovocytes/effets des médicaments et des substances chimiques , Souris , Récepteur activine, type 2/métabolisme , Ovulation/effets des médicaments et des substances chimiques , Gonadotrophine chorionique/pharmacologie , Hormone folliculostimulante/sang , Ovogenèse/effets des médicaments et des substances chimiques , Induction d'ovulation/méthodes , Fragments Fc des immunoglobulines/pharmacologie , Vieillissement/effets des médicaments et des substances chimiques , Vieillissement/physiologie , Grossesse , Activines
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...